Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • leontp587
    Junior Member
    • Jul 2014
    • 6

    #1

    Question about genotype and +/- strands

    Hi everyone,

    I'm new to bioinformatics and have a basic question.

    On Snepedia, Rs1333049 (http://snpedia.com/index.php/Rs1333049) has the following genotype vs clinical effect information:
    Chromosome: 9
    Orientation: plus

    Geno: Summary
    (C;C): 1.9x increased risk for CAD
    (C;G): 1.5x increased risk for CAD
    (G;G): normal

    Does this mean that a person with a plus strand of C and minus strand of G on one chromosome 9 and the same on the other homologous chromosome 9, he/she will have 1.9x risk of CAD? And, if the plus strand was G and the minus strand was C on both chromosomes, then the risk is normal?

    This is probably a very basic question. I just wanted to ask to see if I understand genotypes and plus/minus strands correctly.

    Thanks!
  • Brian Bushnell
    Super Moderator
    • Jan 2014
    • 2709

    #2
    Genotype refers to the allele on the plus strand regardless of whether a gene is read from the plus or minus strand. And yes, your understanding of risk is correct.

    Comment

    • gringer
      David Eccles (gringer)
      • May 2011
      • 845

      #3
      I prefer to avoid complementary mutations (if possible) due to ambiguity around genotyping. Without surrounding sequence you can't tell what strand a variant comes from, which can lead to a great deal of confusion.

      This is a particular issue when validating your variant information. I've had a few cases where a sequenom service provider has used a strand for genotyping that is the opposite from what HapMap, Illumina, or Affymetrix used. For non-complementary variants this is an easy and obvious fix, but it's much trickier when you have C/G or A/T variants.

      Comment

      • leontp587
        Junior Member
        • Jul 2014
        • 6

        #4
        Originally posted by gringer View Post
        I prefer to avoid complementary mutations (if possible) due to ambiguity around genotyping. Without surrounding sequence you can't tell what strand a variant comes from, which can lead to a great deal of confusion.

        This is a particular issue when validating your variant information. I've had a few cases where a sequenom service provider has used a strand for genotyping that is the opposite from what HapMap, Illumina, or Affymetrix used. For non-complementary variants this is an easy and obvious fix, but it's much trickier when you have C/G or A/T variants.
        Thank you everyone for your answers. It's much clearer now.

        I definitely agree it's more challenging about complementary mutations, hopefully eventually there will be a widely followed consensus on how to genotype, because certainly it makes biological sense to have C/G or A/T variants.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
          by SEQadmin2



          Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

          Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
          ...
          10-14-2026, 09:55 AM
        • SEQadmin2
          New Genomics Technologies Take Aim at Long-Standing Limits
          by SEQadmin2


          Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

          We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
          ...
          09-28-2026, 10:25 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Yesterday, 11:13 AM
        0 responses
        19 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, Yesterday, 10:48 AM
        0 responses
        18 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-15-2026, 10:52 AM
        0 responses
        36 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-14-2026, 05:39 AM
        0 responses
        42 views
        0 reactions
        Last Post SEQadmin2  
        Working...